Physician profile
Nayla Chaptini
NPI 1841434024
$1,538.96
in general payments reported to CMS, 2019-2025
10 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.82 · 2020: $36.34 · 2021: $190 · 2022: $190 · 2023: $379 · 2024: $245 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $711.01 | 2021-2025 | |
| Boston Scientific Corporation | $172.00 | 2019-2022 | |
| Pfizer INC. | $153.38 | 2020-2025 | |
| Abbott Laboratories | $147.67 | 2022-2025 | Cardiomems |
| Heartflow, INC. | $145.27 | 2023-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $74.75 | 2023 | Xarelto, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $70.22 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.24 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $18.42 | 2025 | Wegovy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayla Chaptini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.